Catalyst Wire Dossier Catalyst Wire Dossier

Dolutegravir/Abacavir/Lamivudine

dolutegravir/abacavir/lamivudine · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dolutegravir/Abacavir/Lamivudine, covering 2016-10-31 to 2016-10-31. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) [Phase 3]

See pricing